[en] Toxic epidermal necrolysis (TEN) is a rare drug-induced life-threatening disease. Currently, the disease is only treated by supportive and antiseptic measures. Quite recently intravenous immunoglobulins (IG) were shown to be a promising TEN treatment. The rationale for their use is based on the fact that keratinocyte apoptosis in TEN involves the CD95 (APO-1/Fas) cell
surface receptor–ligand system. We successfully treated a TEN patient with high dose of intravenous IG. The clinical recovery appeared exceptionally rapid. Immunohistochemistry showed that the IG action probably developed on the CD95 receptor–ligand system at the keratinocytes surface.
Paquet P., Piérard G.E. (1999) Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis?. Dermatology 198:198-202.
Wolkenstein P., Chanthavy T., Lecoeur S. (1998) Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem. Biol. Interact. 113:39-50.
Herndon D.N. (1995) Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J. Am. Coll. Surg. 180:340-342.
Wolkenstein P., Latarjet J., Roujeau J.C. (1998) Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352:1586-1589.
Furubacke A., Berlin G., Anderson C., Sjoberg F. (1999) Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?. Int. Care Med. 25:1307-1310.
Viard I., Wehrli P., Bullani R. (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490-492.
Magena S., Lisboa C., Goncalves E., Conceicao P., Leal V., Mesquista-Guimaraes J. (2000) A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. Br. J. Dermatol. 142:191-192.
Muller M., Strand S., Hug H. (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99:403-413.
Sung K.J., Paik E.M., Jang K.A., Suh H.S., Choi J.H. (1997) Apoptosis is induced by anti-Fas antibody alone in cultured human keratinocytes. J. Dermatol. 24:427-434.
Oishi M., Maeda K., Sugiyama S. (1994) Distribution of apoptosis-mediating Fas antigen in human skin and effect of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines. Arch. Dermatol. Res. 286:396-407.
De Maria R., Testi R. (1998) Fas-FasL interactions: a common pathogenic mechanism in organ-specific autoimmunity. Immunol Today 19:121-125.
Lee S.H., Jang J.J., Lee J.Y. (1998) Fas ligand is expressed in normal skin and in some cutaneous malignancies. Br. J. Dermatol. 139:186-191.
Hill L.L., Ouhtit A., Loughlin F. (1999) Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science 285:898-900.
Arnold R., Seifert M., Asadullah K., Volk H.D. (1999) Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines. J. Immunol. 162:7140-7147.
